Items where authors include "Paneesha, S"

Article

Hillmen, P, Pitchford, A, Bloor, A et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Munir, T, Emmerson, J orcid.org/0000-0002-8198-8043, Hockaday, A et al. (9 more authors) (2022) Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology, 199 (5). pp. 707-719. ISSN 0007-1048

Allsup, D, Howard, D, Emmerson, J orcid.org/0000-0002-8198-8043 et al. (10 more authors) (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology. ISSN 0007-1048

Agathanggelou, A, Smith, E, Davies, NJ et al. (20 more authors) (2017) USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood, 130 (2). pp. 156-166. ISSN 0006-4971

Proceedings Paper

Munir, T, Howard, D orcid.org/0000-0003-3333-9783, McParland, L et al. (10 more authors) (2018) Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood-Initial results of UK NCRI Phase II/III GALACTIC trial. In: British Journal of Haematology. 58th Annual Scientific Meeting of the British Society for Haematology, 16-18 Apr 2018, Liverpool, UK. Wiley , p. 79.